Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH

Empagliflozin, an established treatment for type 2 diabetes (T2DM), has shown beneficial effects on liver steatosis and fibrosis in animals and in humans with T2DM, non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). However, little is known about the effects of empagliflozin on li...

Descripción completa

Detalles Bibliográficos
Autores principales: Perakakis, Nikolaos, Chrysafi, Pavlina, Feigh, Michael, Veidal, Sanne Skovgard, Mantzoros, Christos S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232001/
https://www.ncbi.nlm.nih.gov/pubmed/34199317
http://dx.doi.org/10.3390/ijms22126332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232001/
https://www.ncbi.nlm.nih.gov/pubmed/34199317
http://dx.doi.org/10.3390/ijms22126332

Ejemplares similares